Jim Cramer on Royalty Pharma: “It’s a Terrific Company”

Company Overview - Royalty Pharma plc (NASDAQ:RPRX) specializes in acquiring royalties for various drugs and funding new research in the biotech sector, with a diverse portfolio that includes treatments for cancer and rare diseases [2] Recent Developments - On January 11, Royalty Pharma announced a funding agreement with Teva Pharmaceuticals to expedite the clinical development of TEV-'408, an anti-IL-15 antibody aimed at treating several autoimmune diseases [2] - CEO Pablo Legorreta emphasized the importance of addressing chronic autoimmune conditions like vitiligo, which have significant emotional and psychosocial impacts, highlighting Royalty Pharma's commitment to funding innovative therapies [2] Market Sentiment - Jim Cramer expressed a positive outlook on Royalty Pharma, noting its consistent growth and the company's role in funding biotechnology, indicating strong confidence in its business model [1]